Epidemiology, clinical ramifications, and cellular pathogenesis of COVID-19 mRNA-vaccination-induced adverse cardiovascular outcomes: A state-of-the-heart review.
COVID-19 mRNA vaccine
COVID-19 myocarditis
COVID-19 perimyocarditis
Coronavirus 2019 (COVID-19)
SARS-CoV-2
Takotsubo syndrome
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
08
02
2022
revised:
10
03
2022
accepted:
17
03
2022
pubmed:
25
3
2022
medline:
28
4
2022
entrez:
24
3
2022
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) has overwhelming healthcare systems globally. To date, a myriad of therapeutic regimens has been employed in an attempt to curb the ramifications of a severe COVID-19 infection. Amidst the ongoing pandemic, the advent and efficacious uptake of COVID-19 vaccination has significantly reduced disease-related hospitalizations and mortality. Nevertheless, many side-effects are being reported after COVID-19 vaccinations and myocarditis is the most commonly reported sequelae post vaccination. Majority of these diseases are associated with COVID-19 mRNA vaccines. Various studies have established a temporal relationship between these complications, yet the causality and the underlying pathogenesis remain hypothetical. In this review, we aim to critically appraise the available literature regarding the cardiovascular side effects of the various mRNA vaccines and the associated pathophysiology.
Identifiants
pubmed: 35325848
pii: S0753-3322(22)00231-1
doi: 10.1016/j.biopha.2022.112843
pmc: PMC8934717
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Messenger
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
112843Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Références
Am J Cardiol. 2022 Jan 1;162:207
pubmed: 34702550
Rev Med Interne. 2021 Nov;42(11):797-800
pubmed: 34740463
Eur J Intern Med. 2021 Oct;92:28-30
pubmed: 34518081
JAMA Cardiol. 2021 Oct 1;6(10):1202-1206
pubmed: 34185045
Diabetes Metab Res Rev. 2022 Jan;38(1):e3465
pubmed: 33955644
JACC Cardiovasc Interv. 2021 May 10;14(9):e103-e104
pubmed: 33958175
J Cardiol Cases. 2021 Nov;24(5):223-226
pubmed: 34539938
Glob Cardiol Sci Pract. 2021 Oct 30;2021(3):e202118
pubmed: 34805376
BMJ. 2021 Mar 11;372:n699
pubmed: 33707182
JAMA Cardiol. 2021 Oct 1;6(10):1196-1201
pubmed: 34185046
Clin Infect Dis. 2022 Aug 24;75(1):e749-e754
pubmed: 34734240
J R Soc Interface. 2021 Sep;18(182):20210214
pubmed: 34465208
Clin Ther. 2013 May;35(5):563-71
pubmed: 23490289
Cureus. 2021 Mar 2;13(3):e13651
pubmed: 33824804
Ann Med Surg (Lond). 2021 Apr 15;65:102291
pubmed: 33981423
Am J Emerg Med. 2013 Nov;31(11):1627.e1-4
pubmed: 23891597
J Hum Hypertens. 2021 Jan;35(1):4-11
pubmed: 32719447
MMWR Morb Mortal Wkly Rep. 2021 Sep 03;70(35):1228-1232
pubmed: 34473684
Cureus. 2020 Jan 3;12(1):e6556
pubmed: 32042529
Expert Rev Clin Immunol. 2010 Sep;6(5):777-88
pubmed: 20828286
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
JAMA. 2021 Sep 28;326(12):1210-1212
pubmed: 34347001
Cell Mol Immunol. 2018 Jun;15(6):586-594
pubmed: 29503439
QJM. 2021 Sep 29;:
pubmed: 34586408
Front Med (Lausanne). 2020 Dec 03;7:594495
pubmed: 33344479
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Am J Cardiol. 2021 Oct 1;156:129-131
pubmed: 34364657
J Am Coll Cardiol. 2004 Jul 7;44(1):201-5
pubmed: 15234435
Vaccines (Basel). 2021 Sep 18;9(9):
pubmed: 34579279